FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012033679> ?p ?o ?g. }

• W2012033679 endingPage "75" @default.
• W2012033679 startingPage "67" @default.
• W2012033679 abstract "Background Increasing numbers of patients with resectable pancreatic cancer are receiving neoadjuvant therapy. Biliary drainage with plastic stents during this period can be associated with recurrent episodes of stent occlusion resulting in unplanned ERCPs and interruptions in therapy. Objective To evaluate the efficacy and safety of self-expandable metal stents (SEMSs) during the neoadjuvant period for resectable pancreatic cancer. Design Patients with proven pancreatic adenocarcinoma with biliary obstruction underwent placement of SEMSs, and data on stent patency and complication rates were collected prospectively. Setting Tertiary-care referral center. Patients This study involved 55 patients with resectable and borderline resectable pancreatic duct adenocarcinoma who were recruited between March 2009 and December 2010. Intervention SEMSs were placed for biliary decompression. The shortest length of stent required to bridge the stricture was used so as to leave enough of the normal bile duct above the stent available for subsequent surgical anastomosis. Endoscopic reintervention was performed in those with stent malfunction. Stents were not removed before surgery. Main Outcome Measurements Stent patency rate during the neoadjuvant period, stent malfunction rate, and complication rates. Information on stent-related difficulties, if any, during surgery. Results Fifty-five patients were recruited (29 men, 26 women; age, mean [± SD] 65.9 ± 11 years; resectable 23, borderline resectable 32). Median time for neoadjuvant therapy and restaging before surgery was 104 days (range 70-260 days). At the median time of 104 days, 88% of SEMSs remained patent. By 260 days, stent malfunction occurred in 15% of patients. These included stent occlusion in 13% and stent migration in 2%. SEMS malfunction occurred in 3 of 27 patients (11%) who ultimately underwent pancreaticoduodenectomy and in 5 of 21 patients (24%) with disease progression (P = not significant). The presence of SEMSs did not interfere with pancreaticoduodenectomy in any patients who underwent surgery. Limitations Nonrandomized study. Conclusion SEMSs are effective and safe in achieving durable biliary drainage in patients with pancreatic cancer receiving neoadjuvant therapy. It is not necessary to remove SEMSs before surgery if the shortest length of stent required to bridge the stricture is used. Increasing numbers of patients with resectable pancreatic cancer are receiving neoadjuvant therapy. Biliary drainage with plastic stents during this period can be associated with recurrent episodes of stent occlusion resulting in unplanned ERCPs and interruptions in therapy. To evaluate the efficacy and safety of self-expandable metal stents (SEMSs) during the neoadjuvant period for resectable pancreatic cancer. Patients with proven pancreatic adenocarcinoma with biliary obstruction underwent placement of SEMSs, and data on stent patency and complication rates were collected prospectively. Tertiary-care referral center. This study involved 55 patients with resectable and borderline resectable pancreatic duct adenocarcinoma who were recruited between March 2009 and December 2010. SEMSs were placed for biliary decompression. The shortest length of stent required to bridge the stricture was used so as to leave enough of the normal bile duct above the stent available for subsequent surgical anastomosis. Endoscopic reintervention was performed in those with stent malfunction. Stents were not removed before surgery. Stent patency rate during the neoadjuvant period, stent malfunction rate, and complication rates. Information on stent-related difficulties, if any, during surgery. Fifty-five patients were recruited (29 men, 26 women; age, mean [± SD] 65.9 ± 11 years; resectable 23, borderline resectable 32). Median time for neoadjuvant therapy and restaging before surgery was 104 days (range 70-260 days). At the median time of 104 days, 88% of SEMSs remained patent. By 260 days, stent malfunction occurred in 15% of patients. These included stent occlusion in 13% and stent migration in 2%. SEMS malfunction occurred in 3 of 27 patients (11%) who ultimately underwent pancreaticoduodenectomy and in 5 of 21 patients (24%) with disease progression (P = not significant). The presence of SEMSs did not interfere with pancreaticoduodenectomy in any patients who underwent surgery. Nonrandomized study. SEMSs are effective and safe in achieving durable biliary drainage in patients with pancreatic cancer receiving neoadjuvant therapy. It is not necessary to remove SEMSs before surgery if the shortest length of stent required to bridge the stricture is used." @default.
• W2012033679 created "2016-06-24" @default.
• W2012033679 creator A5001851791 @default.
• W2012033679 creator A5044819265 @default.
• W2012033679 creator A5067596939 @default.
• W2012033679 creator A5076270097 @default.
• W2012033679 creator A5076913642 @default.
• W2012033679 date "2012-07-01" @default.
• W2012033679 modified "2023-10-15" @default.
• W2012033679 title "Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study" @default.
• W2012033679 cites W1892409143 @default.
• W2012033679 cites W1930757563 @default.
• W2012033679 cites W1969887526 @default.
• W2012033679 cites W1975552920 @default.
• W2012033679 cites W1987027963 @default.
• W2012033679 cites W1987265553 @default.
• W2012033679 cites W1992931496 @default.
• W2012033679 cites W2024477013 @default.
• W2012033679 cites W2050575833 @default.
• W2012033679 cites W2057845230 @default.
• W2012033679 cites W2058509419 @default.
• W2012033679 cites W2072914511 @default.
• W2012033679 cites W2074121131 @default.
• W2012033679 cites W2075244358 @default.
• W2012033679 cites W2090448540 @default.
• W2012033679 cites W2097421939 @default.
• W2012033679 cites W2117009632 @default.
• W2012033679 cites W2133853120 @default.
• W2012033679 cites W2138369377 @default.
• W2012033679 cites W2166509687 @default.
• W2012033679 cites W2179136111 @default.
• W2012033679 doi "https://doi.org/10.1016/j.gie.2012.02.041" @default.
• W2012033679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22483859" @default.
• W2012033679 hasPublicationYear "2012" @default.
• W2012033679 type Work @default.
• W2012033679 sameAs 2012033679 @default.
• W2012033679 citedByCount "103" @default.
• W2012033679 countsByYear W20120336792012 @default.
• W2012033679 countsByYear W20120336792013 @default.
• W2012033679 countsByYear W20120336792014 @default.
• W2012033679 countsByYear W20120336792015 @default.
• W2012033679 countsByYear W20120336792016 @default.
• W2012033679 countsByYear W20120336792017 @default.
• W2012033679 countsByYear W20120336792018 @default.
• W2012033679 countsByYear W20120336792019 @default.
• W2012033679 countsByYear W20120336792020 @default.
• W2012033679 countsByYear W20120336792021 @default.
• W2012033679 countsByYear W20120336792022 @default.
• W2012033679 countsByYear W20120336792023 @default.
• W2012033679 crossrefType "journal-article" @default.
• W2012033679 hasAuthorship W2012033679A5001851791 @default.
• W2012033679 hasAuthorship W2012033679A5044819265 @default.
• W2012033679 hasAuthorship W2012033679A5067596939 @default.
• W2012033679 hasAuthorship W2012033679A5076270097 @default.
• W2012033679 hasAuthorship W2012033679A5076913642 @default.
• W2012033679 hasConcept C121608353 @default.
• W2012033679 hasConcept C126322002 @default.
• W2012033679 hasConcept C126838900 @default.
• W2012033679 hasConcept C141071460 @default.
• W2012033679 hasConcept C2778292576 @default.
• W2012033679 hasConcept C2778583881 @default.
• W2012033679 hasConcept C2779777945 @default.
• W2012033679 hasConcept C2780210213 @default.
• W2012033679 hasConcept C2781182431 @default.
• W2012033679 hasConcept C530470458 @default.
• W2012033679 hasConcept C71924100 @default.
• W2012033679 hasConcept C8443397 @default.
• W2012033679 hasConceptScore W2012033679C121608353 @default.
• W2012033679 hasConceptScore W2012033679C126322002 @default.
• W2012033679 hasConceptScore W2012033679C126838900 @default.
• W2012033679 hasConceptScore W2012033679C141071460 @default.
• W2012033679 hasConceptScore W2012033679C2778292576 @default.
• W2012033679 hasConceptScore W2012033679C2778583881 @default.
• W2012033679 hasConceptScore W2012033679C2779777945 @default.
• W2012033679 hasConceptScore W2012033679C2780210213 @default.
• W2012033679 hasConceptScore W2012033679C2781182431 @default.
• W2012033679 hasConceptScore W2012033679C530470458 @default.
• W2012033679 hasConceptScore W2012033679C71924100 @default.
• W2012033679 hasConceptScore W2012033679C8443397 @default.
• W2012033679 hasIssue "1" @default.
• W2012033679 hasLocation W20120336791 @default.
• W2012033679 hasLocation W20120336792 @default.
• W2012033679 hasOpenAccess W2012033679 @default.
• W2012033679 hasPrimaryLocation W20120336791 @default.
• W2012033679 hasRelatedWork W2052538295 @default.
• W2012033679 hasRelatedWork W2091850843 @default.
• W2012033679 hasRelatedWork W2142342386 @default.
• W2012033679 hasRelatedWork W2153618163 @default.
• W2012033679 hasRelatedWork W2197314980 @default.
• W2012033679 hasRelatedWork W2391490740 @default.
• W2012033679 hasRelatedWork W2418199038 @default.
• W2012033679 hasRelatedWork W2444375365 @default.
• W2012033679 hasRelatedWork W3030740161 @default.
• W2012033679 hasRelatedWork W4292846046 @default.
• W2012033679 hasVolume "76" @default.
• W2012033679 isParatext "false" @default.
• W2012033679 isRetracted "false" @default.
• W2012033679 magId "2012033679" @default.

• next